Compare · PM vs PXMD
PM vs PXMD
Side-by-side comparison of Philip Morris International Inc (PM) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PM and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM carries a market cap of $292.10B.
- PM has hit the wire 7 times in the past 4 weeks while PXMD has been quiet.
- PM has more recent analyst coverage (25 ratings vs 0 for PXMD).
- Company
- Philip Morris International Inc
- PaxMedica Inc.
- Price
- $187.42-1.67%
- $0.72-3.73%
- Market cap
- $292.10B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Latest PM
- New insider Andolina Massimo claimed ownership of 71,588 shares (SEC Form 3)
- SEC Form 25-NSE filed by Philip Morris International Inc
- SEC Form 10-Q filed by Philip Morris International Inc
- BTIG Research initiated coverage on Philip Morris International with a new price target
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
- Philip Morris International to Host Webcast of 2026 Second-Quarter and First Six-Months Results
- Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PMI U.S. Unveils the ZYN America250 Art Series, Bringing Modern Culture to Limited-Edition Cases
- FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection